ORIC Pharmaceuticals Inc (STU:4TZ)
€ 9.4 0.2 (2.17%) Market Cap: 670.50 Mil Enterprise Value: 407.74 Mil PE Ratio: 0 PB Ratio: 2.30 GF Score: 42/100

Oric Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 21, 2024 / 08:00PM GMT
Release Date Price: €9.5 (-0.52%)
Yigal Nochomovitz
Citi - Analyst

Great. Welcome, everyone. Thanks for sticking with us through the afternoon hours of our first day of the Virtual Oncology Leadership Summit. As you know, I'm Yigal Nochomovitz, that's one of the biotech analyst here at Citigroup. (Conference Instructions)

So with that, it's my great pleasure to have with me senior leadership on ORIC, Jacob Chacko, the CEO; Dominic Piscitelli, CFO; Pratik Multani, the CMO. So thank you all so much for taking the time. It's a story than a lot of the people listening are familiar with.

Questions & Answers

Yigal Nochomovitz
Citi - Analyst

But nonetheless, Jacob, I think helpful to set the stage for us. Give us a quick sense of the pipeline. What are the key priorities for the company over the course of 2024?

Jacob Chacko
ORIC Pharmaceuticals, Inc. - President, CEO & Board Member

Sure. Thank you for having, Yigal. I think most folks are well familiar with the pipeline, so I keep my introductory comments quite quick. We are a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot